Hemoglobin S Promotes Glycemic Dysregulation in a Mouse Model of Human Sickle Cell Disease
Endocrinology · 2025
DOI: 10.1210/endocr/bqaf082 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology, 2025. Verfasst von Joseph Louis Zapater und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Blood Glucose, Hemoglobin, Sickle. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, VA, BLRD VA.
Abstract (Originalsprache)
Hemoglobin S (HbS) presents a challenge to identifying glycemic dysregulation, as changes in red blood cell turnover produce inaccurate hemoglobin A1c (HbA1c) and incongruencies between HbA1c and other glycemic control measures. Concerningly, the prevalence of diabetes in those with HbS is rising, and studies demonstrate that HbS increases the risk of diabetes-related complications. Though a link between the sickle cell variant and HbA1c is reported, the precise mechanisms by which HbS affects glycemic control are unknown. Here, we utilized the Townes mouse model of sickle cell disease (SCD) to analyze the effect of sickle cell trait (SCT) and SCD on glucose homeostasis. We found that chow-fed SCD mice had greater ad libitum and fasting blood glucose than SCT or littermate controls from 8 to 20 weeks of age, along with declining fasting serum insulin with aging, regardless of sex. This was not a result of overt alterations in peripheral glucose or insulin tolerance, gross morphological changes in pancreatic structure, or deposition of iron in pancreatic islets. Furthermore, compared with age- and sex-matched SCT and littermate control mice, we found decreased pancreatic insulin content in 20-week-old SCD male mice and significantly reduced pancreatic islet area and β cell mass in SCD males and females. These findings suggest that having 2 copies of the HbS gene promotes early hyperglycemia and the development of pancreatic β cell dysfunction, which may enhance the risk for diabetes in this cohort.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
- Department of Medicine, Jesse Brown VA Medical Center, Chicago, IL 60612, USA.
- Department of Medicine, Internal Medicine Residency, University of Illinois at Chicago, Chicago, IL 60612, USA.
- Division of Hematology and Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
ORCID-Profile: Joseph Louis Zapater, Nadia Saib Sweis, Santosh Lumdas Saraf, Brian Thomas Layden
Förderung
- NHLBI NIH HHS
- VA
- BLRD VA
- NIDDK NIH HHS
- NIH HHS
- NIH
Zitieren
APA
Zapater, J. L., Nicholoff, S. T., Sweis, N. S., Saraf, S. L., & Layden, B. T. (2025). Hemoglobin S Promotes Glycemic Dysregulation in a Mouse Model of Human Sickle Cell Disease. Endocrinology. https://doi.org/10.1210/endocr/bqaf082
Vancouver
Zapater JL, Nicholoff ST, Sweis NS, Saraf SL, Layden BT. Hemoglobin S Promotes Glycemic Dysregulation in a Mouse Model of Human Sickle Cell Disease. Endocrinology. 2025. doi:10.1210/endocr/bqaf082
BibTeX
@article{Zapater2025,
author = {Zapater, Joseph Louis and Nicholoff, Seth Thomas and Sweis, Nadia Saib and Saraf, Santosh Lumdas and Layden, Brian Thomas},
title = {Hemoglobin S Promotes Glycemic Dysregulation in a Mouse Model of Human Sickle Cell Disease},
journal = {Endocrinology},
year = {2025},
doi = {10.1210/endocr/bqaf082}
}
EUVIMED